Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver

Bone Marrow Transplantation

Volumn 21, Issue 2, 1998, Pages 117-122

  Fisher, D C ^a   Vredenburgh, J J ^a   Petros, W P ^a   Hussein, A ^a   Berry, D A ^a   Elkordy, M ^a   Rubin, P ^a   Gilbert, C J ^a   Peters, W P ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; High dose chemotherapy; PBPC; Veno occlusive disease

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AXILLARY LYMPH NODE; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CAUSE OF DEATH; CELL TRANSPLANTATION; CONTROLLED STUDY; FEMALE; HUMAN; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MORBIDITY; PRIORITY JOURNAL; STEM CELL; SURVIVAL TIME;

EID: 0031962799     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701068     Document Type: Article

References (31)

1. Peters WP, Shpall EJ, Jones R et al. High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6; 1368-1376.
2. Williams S, Mick R, Desser R et al. High dose consolidation therapy with autologous stem cell rescue in Stage IV breast cancer. J Clin Oncol 1989; 7: 1824-1830.
3. Peters WP, Ross M, Vredenburgh JJ et al. High dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
4. Sobocinski KA, Horowitz M, Rowlings P et al. Bone Marrow Transplantation-1994: a report from the international bone marrow transplant registry and the north American autologous bone marrow transplant registry. J Hematother 1994; 3; 95-102.
5. Peters WP, Rosner G, Ross M et al. Comparative effects of granulocyte-macrophage colony stimulating factor (gm-csf) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high dose chemotherapy. Blood 1993; 81: 1709-1719.
6. Chao NJ, Schriber JR, Grimes K et al. Granulocyte colonystimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031-2035.
7. Kritz A, Crown J, Motzer RJ et al. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. Cancer 1993; 71: 2515-2521.
8. Jones RB, Shpall EJ, Ross M et al. AFM induction chemotherapy, followed by intensive alkylating agent consolidation with autologous bone marrow support (ABMS) for advanced breast cancer. Current results. Proc Am Soc Clin Oncol 1990; 9: 9.
9. Peters WP, Jones RB, Vredenburgh JJ et al. A large prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Presented during the 18th Annual San Antonio Breast Cancer Symposium. December 8-13, 1995, San Antonio, Texas. Breast Cancer Res Treat 1995; 37 (Suppl.): 35.
10. Jones RB, Shpall EJ, Shogan J et al. The Duke AFM program: intensive induction chemotherapy for metastatic breast cancer. Cancer 1990; 66: 431-436.
11. Peters WP, Eder JP, Henner WD et al. High dose combination alkylating agents with autologous bone marrow support: A phase I trial. J. Clin Oncol 1986; 4: 646-654.
12. Agresti A. Categorical Data Analysis. John Wiley & Sons: New York, 1990, p 230.
13. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia by chemotherapy in patients with small-cell lung cancer. New Engl J Med 1991; 325: 164-170.
14. Nemunaitis J, Singer JW, Buckner D et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation for lymphoid malignancies. Blood 1988; 72: 834-836.
15. McDonald GB, Hinds M, Fisher L et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
16. Jones RJ, Lee KSK, Beschmomer WF et al. Veno-occlusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
17. Ganem G, Saint-Marc Girardin MF, Kuentz M et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in man. Int J Rad Oncol Biol Phys 1988; 14: 879-884.
18. Shulman HM, McDonald GB, Matthews D et al. An analysis of hepatic veno-occlusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 1980; 79: 1178-1191.
19. Shulman HM, Gown AM, Nugent DJ et al. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol 1987; 127: 549-558.
20. Essell JH, Thompson JN, Harman GS et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1992; 79: 2784-2788.
21. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis and acute graft versus host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
22. Holler E, Kolb HJ, Moller A et al. Increased serum levels of tumor necrosis factor-alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-1016.
23. Anscher MS, Peters WP, Reisenbichler H et al. Transforming growth factor-beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. New Engl J Med 1993; 328: 1592-1598.
24. Rabinowitz J, Petros WP, Stuart A, Peters WP. Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support. Blood 1993; 81: 2452-2459.
25. Harper PL, Jarvis J, Jennings I et al. Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transplant 1990; 5: 39-42.
26. Scrobahaci ML, Drouet L, Monem-Mansi A et al. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res 1991; 63: 509-519.
27. Bevilacqua MP, Pober JS, Majeau GR et al. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533-4537.
28. Gerlach H, Esposito C, Stern DM. Modulation of endothelial hemostatic properties: an active role in the host response. Annu Rev Med 1990; 41: 15-24.
29. Jaattela M. Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachexin. Lab Invest 1991; 64: 724-742.
30. Jirtle RL, Carr BI, Scott CD. Modulation of insulin-like growth factor-II/mannose 6-phosphate receptors and transforming growth factor-β1 during liver regeneration. J Biol Chem 1991; 266: 22444-22450. (Erratum, J Biol Chem 1991; 266: 24869).
31. Petros WP, Rosner GL, Rabinowitz J et al. Investigation of the pharmacological effects of recombinant, human colony-stimulating factors and their modulation by theophylline. Pharmacotherapy 1996; 16: 742-748.